Since the founding of the Pharmacokinetics Shared Resource in 1983, the primary mission of the Core has been to facilitate high-quality competitively funded peer-reviewed pharmacokinetic/pharmacodynamic translational research in both clinical and pre-clinical models at the SJ Cancer Center. The objectives are to 1) implement trials with pharmacokinetic studies at the St. Jude Cancer center by assisting with study design, building of standard orders and laboratory test procedures, and educating nursing and other clinical staff 2) efficiently and properly collect, accession, process, and distribute pharmacokinetic samples on these trials and 3) ensure valid, high quality sensitive and specific analyses of anticancer drugs, their metabolites, or other relevant pharmacologic indices in biological samples, and assist with state-of-the-art biomedical pharmacokinetic and pharmacodynamic modelling. The benefits of the Pharmacokinetics Shared Resource to the Cancer Center include: cost-efficiency, consistency in application of state-of-the-art equipment, facilities, and approaches to pharmacokinetic/dynamic projects, standardized operating procedures for regimented, continuous, and thoroughly documented analytical quality control, centralized sample processing and storage, consolidation of resources in a single facility, minimization of invasive collection procedures in children and minimizing the number of animals for preclinical studies, and stimulation of scientific collaborations. Since the last competitive renewal, the LC-MS capacity of the Shared Resource has been greatly enhanced. A chargeback system was begun and is being phased in to apply to all samples processed by the Resource. An intranet site was established with clear explanations for chargebacks and services provided, Dr. Crews joined the shared resource in July 2005 as Co-Director to supervise the day-to-day activities of the core. Dr. Baker joined the core in August 2006 and will take over as Director of the shared resource for this renewal application;Dr. Relling will remain involved as a consultant to ensure a seamless transition in leadership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-33
Application #
8234116
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
33
Fiscal Year
2011
Total Cost
$267,247
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
ElInati, Elias; Russell, Helen R; Ojarikre, Obah A et al. (2017) DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line. Proc Natl Acad Sci U S A 114:12536-12541
Gibson, Todd M; Li, Zhenghong; Green, Daniel M et al. (2017) Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 26:1705-1713
Scott, Daniel C; Hammill, Jared T; Min, Jaeki et al. (2017) Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol 13:850-857
Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314
Penkert, Rhiannon R; Jones, Bart G; Häcker, Hans et al. (2017) Vitamin A differentially regulates cytokine expression in respiratory epithelial and macrophage cell lines. Cytokine 91:1-5
Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2017) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer :
Talleur, Aimee C; Triplett, Brandon M; Federico, Sara et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Hapl Biol Blood Marrow Transplant 23:1910-1917
Wu, Jianrong (2017) Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model. Stat Biopharm Res 9:25-34
Svolos, P; Reddick, W E; Edwards, A et al. (2017) Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. AJNR Am J Neuroradiol 38:1235-1241
Lin, Wenwei; Goktug, Asli N; Wu, Jing et al. (2017) High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor. Assay Drug Dev Technol 15:383-394

Showing the most recent 10 out of 6607 publications